Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02374957Phase 4Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cilostazol in Peripheral Arterial Disease (PAD), sponsored by Wake Forest University Health Sciences. Started Feb 2015; status: terminated.
02
Drugs
cilostazol
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02374957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374957.